Application of metabolomics and microbiome sequencing in diagnosing and monitoring lung disease (COPD, Lung cancer, asthma, infections)

Hywel Dda University Health Board0 个研究点目标入组 2,000 人开始时间: 2017年3月7日最近更新: 2020年7月20日

适应症

试验速览

暂无简介。

•Subjects: patients with a diagnosis of respiratory disease and eventually healthy control volunteers. These will conform to the following categories.
•1. Patients suffering from COPD according to current standard criteria
•2. Age over 40 years
•3. Ex or current smokers of at least 10 pack-years
•4. Post bronchodilator FEV1/FVC<0.70 and FEV1<80% predicted
•Lung Cancer:
•1. Patients referred by their GPs or other specialists with possible diagnosis of lung cancer
•2. Have a smoking history, asbestos exposure or other suspicious symptoms including breathlessness, chest pain, cough, weight loss or exhibits an abnormal chest X-ray
•Healthy Controls:
•1. Spouses and family members of COPD patients
•2. Smokers attending our secondary care smoking cessation service
•3. No symptoms or known diagnoses of lung disease.
•Patients with lung disease other than COPD or Lung Cancer: depending on resources the study will be expanded to include other controls with asthma, bronchiectasis, fibrosis or lung other diseases.

•No exclusion criteria have been defined, except for the good condition of collected samples and reliability of the information provided to the reseachers by the particiapants.

发起方